Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

ABCB4/MDR3 in health and disease – at the crossroads of biochemistry and medicine

(2019) Martin Prescher et al.   BIOLOGICAL CHEMISTRY

Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice

(2019) Yin Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Synthesis, Insecticidal, Fungicidal Activities and Structure–Activity Relationships of Tschimganin Analogs

(2018) Yueting Zhou et al.   MOLECULES

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

(2018) Ying-Bin Hu et al.   Drug Design Development and Therapy

Animal models of cholestasis: An update on inflammatory cholangiopathies

(2018) Valeria Mariotti et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

An update on the recent advances in antifibrotic therapy

(2018) Frank Tacke et al.   Expert Review of Gastroenterology & Hepatology

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis

(2018) Rowan F. van Golen et al.   Scientific Reports

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

(2017) Michael Trauner et al.   HEPATOLOGY

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

Management of cholestatic disease in 2017

(2017) Elsemieke de Vries et al.   LIVER INTERNATIONAL

Therapies in non-alcoholic steatohepatitis (NASH)

(2017) Abdul M. Oseini et al.   LIVER INTERNATIONAL

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

(2017) Adriana Carino et al.   Scientific Reports

Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease

(2016) Emina Halilbasic et al.   DIGESTIVE DISEASES

Obeticholic Acid: First Global Approval

(2016) A. Markham et al.   DRUGS

Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases

(2016) Yanping Xu   JOURNAL OF MEDICINAL CHEMISTRY

Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances

(2016) Jennie Ka Ching Lau et al.   JOURNAL OF PATHOLOGY

Obeticholic acid for PBC

(2016) Hugh Thomas   Nature Reviews Gastroenterology & Hepatology

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

(2016) Len Verbeke et al.   Scientific Reports

Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor

(2016) Ming Gu et al.   Frontiers in Pharmacology

Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame

(2015) Samar H. Ibrahim et al.   DIGESTIVE DISEASES AND SCIENCES

Recent advances in the exploration of the bile salt export pump (BSEP/ABCB11) function

(2015) Ágnes Telbisz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

(2015) Ulrich Beuers et al.   JOURNAL OF HEPATOLOGY

The carbon tetrachloride model in mice

(2015) D Scholten et al.   LABORATORY ANIMALS

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice

(2013) Jittima Weerachayaphorn et al.   JOURNAL OF HEPATOLOGY

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

(2012) Luciano Adorini et al.   DRUG DISCOVERY TODAY

Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese

(2012) Chun-Jen Liu   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− (Abcb4 −/− ) mouse cholangiopathy model by promoting biliary HCO 3− output

(2011) Anna Baghdasaryan et al.   HEPATOLOGY

Antibacterial mono- and sesquiterpene esters of benzoic acids from Iranian propolis

(2010) Boryana Trusheva et al.   Chemistry Central Journal

A common polymorphism in theABCB11gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease

(2010) Rika Iwata et al.   CLINICAL SCIENCE

Cholangiocyte proliferation and liver fibrosis

(2009) Shannon S. Glaser et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

La transplantation hépatique

(2009) C. Duvoux et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

(2008) Yan-Dong Wang et al.   HEPATOLOGY

Liver cirrhosis

(2008) Detlef Schuppan et al.   LANCET